Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis

Recruiting N/A Interventional Study
Female Infertility NF-κB Ligand RANKL Osteoporosis Follicle Development
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Study type
Interventional
Purpose
Treatment
Participants needed
100 (estimated)
Sponsor
Peter Humaidan · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Female infertility presents a significant societal challenge that will be aggravated in the future due to delayed parenthood. Our translational research suggests that receptor activator of NF-κB ligand (RANKL) is a novel treatment target, during assisted reproductive techniques and that inhibition of this pathway may reduce the impact of aging on the ovary. RANKL is a regulator of bone health, and…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Female in the age of 18 or above, Normal AMH-value, able to give concent Exclusion Criteria: * Patients who have had autotransplanted ovarian tissue
Contacts

No contact information available.